New Investigational Drug’s Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects

References

• World Health Organization. Cervical cancer; 2023. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer. [Accessed 2023 Sept 8].
   Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures, 2022. Atlanta, GA: American Cancer Society, Inc; 2022.
   Google Scholar
• Conway MJ, Meyers C. Replication and assembly of human papilloma viruses. J Dent Res. 2009;88(4):307–317. doi:10.1177/0022034509333446.
   PubMed Web of Science ®Google Scholar
• Cervical cancer – Risk factors. https://www.cancer.net/cancer-types/cervical-cancer/risk-factors. [Accessed 2023 Apr 10].
   Google Scholar
• Centers for Disease Control and Prevention. What are the risk factors for cervical cancer?; 2023. https://www.cdc.gov/cancer/cervical/basic_info/risk_factors.htm. [Accessed 2023 Apr 10].
   Google Scholar
• Mayo Clinic: a Mayo foundation for medical education and research (MFMER). Cervical cancer: symptoms and causes; 2023. https://www.mayoclinic.org/diseases-conditions/cervical-cancer/symptoms-causes/syc-20352501. [Accessed 2023 Apr 10].
   Google Scholar
• National Cancer Institute. Cancer staging; 2023. https://www.cancer.gov/about-cancer/diagnosis-staging/staging. [Accessed 2023 Apr 10].
   Google Scholar
• Kurman RJ, Carcangiu ML, Young RH, Herrington S. WHO classification of tumours of female reproductive organs. 4th ed. Lyon, France: International Agency for Research on Cancer; 2014.
   Google Scholar
• Salicrú SR, de la Torre JF, Gil-Moreno A. The surgical management of early-stage cervical cancer. Curr Opin Obstet Gynecol. 2013;25(4):312–319. doi:10.1097/GCO.0b013e3283630d6a.
   PubMed Web of Science ®Google Scholar
• Cervical cancer- diagnose, evaluation and treatment, Radiology Info 2023, Illionis, US: Radiological Society of North America; 2023.https://www.radiologyinfo.org/en/info/cervicalcancer [Accessed 2023 Apr 10].
   Google Scholar
• Bizzarri N, Ghirardi V, Alessandri F, Venturini PL, Valenzano Menada M, Rundle S, et al. Bevacizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2016;16(3):407–419. doi:10.1517/14712598.2016.1145208.
   PubMed Web of Science ®Google Scholar
• Barra F, Lorusso D, Leone Roberti Maggiore U, Ditto A, Bogani G, Raspagliesi F, Ferrero S. Investigational drugs for the treatment of cervical cancer. Expert Opin Investig Drugs. 2017;26(4):389–402. doi:10.1080/13543784.2017.1302427.
   PubMed Web of Science ®Google Scholar
• Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7 Suppl 4(S4):2–8. doi:10.1634/theoncologist.7-suppl_4-2.
   PubMedGoogle Scholar
• Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999;5(3):577–586. PMID: 10100709.
   PubMed Web of Science ®Google Scholar
• Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 2011;22(10):2166–2178. Epub 2011 Feb 16. PMID: 21325449. doi:10.1093/annonc/mdq723.
   PubMed Web of Science ®Google Scholar
• Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A, Friese K. Cetuximab monotherapy in advanced cervical cancer: A retrospective study with five patients. Arch Gynecol Obstet. 2011;283(1):109–113. doi:10.1007/s00404-010-1389-1.
   PubMed Web of Science ®Google Scholar
• Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol. 2009;113(1):16–20. doi:10.1016/j.ygyno.2008.12.040.
   PubMed Web of Science ®Google Scholar
• Blohmer J, Gore M, Kuemmel S, Verheijen RH, Kimmig R, Massuger A, Du Bois LFAG, et al. Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer. JCO. 2005;23(16_suppl):2534–2534. doi:10.1200/jco.2005.23.16_suppl.2534.
   PubMed Web of Science ®Google Scholar
• Rawat SJ, Jain R, Ahmed R. Nimotuzumab with concurrent chemoradiation in the treatment of locally advanced cervical cancer: A single-centre experience. Ind J Gynecol Oncolog. 2020;18(3):92. doi:10.1007/s40944-020-00439-y.
   Web of Science ®Google Scholar
• Chen W, Li T, Wang J, Liang L, Huang D, Yan G, et al. Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer. Cancer Manag Res. 2019;11:8157–8165. doi:10.2147/CMAR.S191134.
   PubMed Web of Science ®Google Scholar
• Qing D, Wu Y, Liu X, Jiang H, Zhu C, Liu P, et al. Long-term results of concurrent chemoradiotherapy combined with anti-EGFR monoclonal antibody prior to surgery in locally advanced cervical cancer: A single-institute prospective study. Cancer Manag Res. 2020;12:12309–12317. doi:10.2147/CMAR.S282372.
   PubMed Web of Science ®Google Scholar
• Chen YF, Tang WB, Pan XX, Wu CR, Cao Y, Yang W. Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer. Onco Targets Ther. 2017;10:4113–4119. doi:10.2147/OTT.S133756.
   PubMed Web of Science ®Google Scholar
• Chen J, Cao YJ, Zhu L, Zhang BL, Liu ZY, Hou HL, et al. Clinical observational study of Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer. Zhonghua Yi Xue Za Zhi. 2021;101(8):597–601. doi:10.3760/cma.j.cn112137-20201104-03011.
   PubMedGoogle Scholar
• Nogueira-Rodrigues A, do Carmo CC, Viegas C, Erlich F, Camisão C, Fontão K, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res. 2008;14(19):6324–6329. doi:10.1158/1078-0432.CCR-07-5112.
   PubMed Web of Science ®Google Scholar
• Nogueira-Rodrigues A, Moralez G, Grazziotin R, Carmo CC, Small IA, Alves FVG, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;120(8):1187–1193. doi:10.1002/cncr.28471.
   PubMed Web of Science ®Google Scholar
• Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108(1):42–46. doi:10.1016/j.ygyno.2007.07.057.
   PubMed Web of Science ®Google Scholar
• Sharma DN, Rath GK, Julka PK, Gandhi AK, Jagadesan P, Kumar S. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia. Int J Gynecol Cancer. 2013;23(4):705–709. doi:10.1097/IGC.0b013e31828b1699.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–364. doi:10.1016/s0092-8674(00)80108-7.
   PubMed Web of Science ®Google Scholar
• Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res. 1996;69:135–174. doi:10.1016/s0065-230x(08)60862-3.
   PubMed Web of Science ®Google Scholar
• Milosevic MF, Townsley CA, Chaudary N, Clarke B, Pintilie M, Fan S, et al. Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: Results of a phase 1 clinical study. Int J Radiat Oncol Biol Phys. 2016;94(1):111–117. doi:10.1016/j.ijrobp.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;29 (36):4845–3569. doi:10.1200/JCO.2009.26.9571.
   Web of Science ®Google Scholar
• Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, et al. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079). Gynecol Oncol. 2022;165(3):413–419. doi:10.1016/j.ygyno.2022.04.011.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nagao S, Shibutani T, Yamamoto K, Jimi T, Yano H, et al. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecol Oncol. 2019;154(3):554–557. doi:10.1016/j.ygyno.2019.05.018.
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130(1):64–68. doi:10.1016/j.ygyno.2013.04.009.
   PubMed Web of Science ®Google Scholar
• Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371–375. Epub 2013 Dec 25. doi:10.1038/nature12881.
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–1945. doi:10.1101/gad.1212704.
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8):671–688. doi:10.1038/nrd2062.
   PubMed Web of Science ®Google Scholar
• Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol Oncol. 2014;133(2):375–381. doi:10.1016/j.ygyno.2014.02.017.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Alp E, Onen HI, Menevse S. Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Contemp Oncol (Pozn). 2016;20(1):28–32. doi:10.5114/wo.2016.58498.
   PubMedGoogle Scholar
• Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010;117(3):473–476. doi:10.1016/j.ygyno.2010.02.022.
   PubMed Web of Science ®Google Scholar
• Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130(2):269–274. doi:10.1016/j.ygyno.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Campos SM, Berlin S, Krasner CN, Whalen C, Atkinson T, Meegan K, et al. A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemother Pharmacol. 2022;89(3):423–430. doi:10.1007/s00280-022-04399-2.
   PubMed Web of Science ®Google Scholar
• Gradwohl G, Ménissier de Murcia JM, Molinete M, Simonin F, Koken M, Hoeijmakers JH, de Murcia G. The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. Proc Natl Acad Sci U S A. 1990;87(8):2990–2994. doi:10.1073/pnas.87.8.2990.
   PubMed Web of Science ®Google Scholar
• Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13(13):3046–3082. doi:10.2741/2909.
   PubMedGoogle Scholar
• Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293–301. doi:10.1038/nrc2812.
   PubMed Web of Science ®Google Scholar
• Reinbolt RE, Hays JL. The role of PARP Inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237. doi:10.3389/fonc.2013.00237.
   PubMedGoogle Scholar
• Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis. 1999;20(2):199–203. doi:10.1093/carcin/20.2.199.
   PubMed Web of Science ®Google Scholar
• Kunos C, Deng W, Dawson D, Lea JS, Zanotti KM, Gray HJ, et al. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG Oncology/Gynecologic Oncology Group study. Int J Gynecol Cancer. 2015;25(3):484–492. doi:10.1097/IGC.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852). Ann Oncol. 2017;28(3):505–511. doi:10.1093/annonc/mdw635.
   PubMed Web of Science ®Google Scholar
• Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6(8):597–610. doi:10.1038/nrg1655.
   PubMed Web of Science ®Google Scholar
• Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6–21. doi:10.1101/gad.947102.
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38. doi:10.1038/npp.2012.112.
   PubMed Web of Science ®Google Scholar
• Verma M, Banerjee HN. Epigenetic inhibitors. Methods Mol Biol. 2015;1238:469–485. doi:10.1007/978-1-4939-1804-1_24.
   PubMedGoogle Scholar
• Kim DH, Kim H-M, Huong PTT, Han H-J, Hwang J, Cha-Molstad H, et al. Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer. BMB Rep. 2019;52(5):342–347. doi:10.5483/BMBRep.2019.52.5.055.
   PubMed Web of Science ®Google Scholar
• Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33(8):2989–2996.
   PubMed Web of Science ®Google Scholar
• Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O, Jr, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol. 2002;25(5):496–501. doi:10.1097/00000421-200210000-00015.
   PubMed Web of Science ®Google Scholar
• Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011;28 Suppl 1(S1):S540–S6. doi:10.1007/s12032-010-9700-3.
   PubMedGoogle Scholar
• Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18(9):1529–1538. doi:10.1093/annonc/mdm204.
   PubMed Web of Science ®Google Scholar
• Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immuno histochemical expression: A gynecologic oncology group study. Gynecol Oncol. 2011;121(2):303–308. doi:10.1016/j.ygyno.2011.01.030.
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, et al. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019;153(3):535–540. doi:10.1016/j.ygyno.2019.03.260.
   PubMed Web of Science ®Google Scholar
• Santin AD, Sill MW, McMeekin DS, Leitao MM, Jr, Brown J, Sutton GP, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A gynecologic oncology group study. Gynecol Oncol. 2011;122(3):495–500. doi:10.1016/j.ygyno.2011.05.040.
   PubMed Web of Science ®Google Scholar
• Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, et al. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012;127(3):456–461. doi:10.1016/j.ygyno.2012.08.030.
   PubMed Web of Science ®Google Scholar
• Lu H, Wu Y, Liu X, Jiang H, Pang Q, Peng L, et al. A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer. Onco Targets Ther. 2018;11:3785–3792. doi:10.2147/OTT.S164071.
   PubMed Web of Science ®Google Scholar
• Redondo A, Colombo N, McCormack M, Dreosti L, Nogueira-Rodrigues A, Scambia G, et al. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol. 2020;159(1):142–149. doi:10.1016/j.ygyno.2020.07.026.
   PubMed Web of Science ®Google Scholar
• Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2017;146(3):554–559. doi:10.1016/j.ygyno.2017.05.033.
   PubMed Web of Science ®Google Scholar
• Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16(15):1515–1524. doi:10.1016/S1470-2045(15)00220-X.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. Gynecol Oncol. 2021;162(2):292–298. doi:10.1016/j.ygyno.2021.05.007.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, et al. Circulating tumor cells in advanced cervical cancer: NRG oncology-gynecologic oncology group study 240 (NCT 00803062). Mol Cancer Ther. 2020;19(11):2363–2370. doi:10.1158/1535-7163.MCT-20-0276.
   PubMed Web of Science ®Google Scholar
• Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997;3(9):1501–1505.
   PubMed Web of Science ®Google Scholar
• de Melo AC, Grazziotin-Reisner R, Erlich F, Fontes Dias MS, Moralez G, Carneiro M, et al. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemother Pharmacol. 2016;78(1):101–109. doi:10.1007/s00280-016-3064-0.
   PubMed Web of Science ®Google Scholar
• Wang H, Shu J, Zou D, Zhou Q. Preliminary results of niraparib and brivanib dual therapy evaluation in recurrent, metastatic and persistent cervical cancer (CQGOG0101): An open-label, phase II clinical trial. JCO. 2021;39(15_suppl):e17506–e17506. doi:10.1200/JCO.2021.39.15_suppl.e17506.
   Web of Science ®Google Scholar
• Candelaria M, Cetina L, Pérez-Cárdenas E, de la Cruz-Hernández E, González-Fierro A, Trejo-Becerril C, et al. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol. 2010;31(4):386–391.
   PubMed Web of Science ®Google Scholar
• Erlotinib in treating patients with persistent or recurrent cancer of the cervix. https://classic.clinicaltrials.gov/ct2/show/NCT00031993. [Accessed 2023 Sept 8].
   Google Scholar
• Adverse effects of erlotinib, https://my.clevelandclinic.org/health/drugs/19308-erlotinib-tablets. [Accessed 2023 Sept 8].
   Google Scholar
• Cetuximab, cisplatin, and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. https://classic.clinicaltrials.gov/ct2/show/NCT00104910. [Accessed 2023 Sept 8].
   Google Scholar
• Štulhofer Buzina D, Martinac I, Ledić Drvar D, Čeović R, Bilić I, Marinović B. Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor. Acta Dermatovenerol Croat. 2016;24(1):70–72.
   PubMed Web of Science ®Google Scholar
• Combination of nimotuzumab cisplatin-vinorelbine in first line chemotherapy in recurring-persistent cervical carcinoma. https://classic.clinicaltrials.gov/ct2/show/NCT02083211. [Accessed 2023 Sept 8].
   Google Scholar
• Zhang L, Jiang Y, Jiang P, Chen Z, Cui H, Zhang Y. Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer. Ann Transl Med. 2022;10(24):1322–1322. doi:10.21037/atm-22-5739.
   PubMed Web of Science ®Google Scholar
• First-line treatment with camrelizumab + apatinib versus chemotherapy + bevacizumab in advanced cervical cancer. https://classic.clinicaltrials.gov/ct2/show/NCT04974944. [Accessed 2023 Sept 8].
   Google Scholar
• Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–1663. doi:10.1016/S0140-6736(17)31607-0.
   PubMed Web of Science ®Google Scholar
• Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. https://classic.clinicaltrials.gov/ct2/show/NCT00430781. [Accessed 2023 Sept 8].
   Google Scholar
• Chuai Y, Rizzuto I, Zhang X, Li Y, Dai G, Otter SJ, et al. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. Cochrane Database Syst Rev. 2021;3(3):CD013348. doi:10.1002/14651858.CD013348.
   PubMedGoogle Scholar
• Sunitinib malate in treating patients with uterine cervical cancer that is stage ivb, recurrent, or cannot be removed by surgery. https://classic.clinicaltrials.gov/ct2/show/NCT00389974. [Accessed 2023 Sept 8].
   Google Scholar
• Temsirolimus in treating patients with cervical cancer that is recurrent, locally advanced, metastatic, or cannot be removed by surgery. https://clinicaltrials.gov/search?cond=temsirolimus%20in%20cervical%20cancer. [Accessed 2023 Sept 8].
   Google Scholar
• Galstyan A, Cho J, Johnson DE, Grandis RJ. Chapter 5 - Modulation of the PI3K/mTOR pathways. In: Cancer sensitizing agents for chemotherapy, improving the therapeutic ratio in head and neck cancer. Vol. 6. Elsevier; 2020. p. 89–105. doi:10.1016/B978-0-12-817868-3.00005-6.
   Google Scholar
• Niraparib in combination with dostarlimab in patients with recurrent or progressive cervix cancer (STAR). https://classic.clinicaltrials.gov/ct2/show/NCT04068753. [Accessed 2023 Sept 8].
   Google Scholar
• Yue F, Shiyi P, Yuwei L, Yu Z, Hongwei Z, Xiangyu E, et al. Effects of the PARP inhibitor Niraparib on the radiosensitivity of human lung and cervical cancer cells. Radiat Med Prot. 2023;4(2):93–97. doi:10.1016/j.radmp.2023.05.002.
   Google Scholar
• Pembrolizumab and olaparib in cervical cancer patients. https://classic.clinicaltrials.gov/ct2/show/NCT04483544. [Accessed 2023 Sept 8].
   Google Scholar
• Alexandraki A, Strati K. Decitabine treatment induces a viral mimicry response in cervical cancer cells and further sensitizes cells to chemotherapy. Int J Mol Sci. 2022;23(22):14042. doi:10.3390/ijms232214042.
   PubMed Web of Science ®Google Scholar
• Kagabu M, Nagasawa T, Sato C, Fukagawa Y, Kawamura H, Tomabechi H, et al. Immunotherapy for uterine cervical cancer using checkpoint inhibitors: Future directions. Int J Mol Sci. 2020;21(7):2335. doi:10.3390/ijms21072335.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847. doi:10.1056/nejmoa0810097.
   PubMed Web of Science ®Google Scholar
• Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol. 2017;12(1):45. doi:10.1186/s13000-017-0631-6.
   PubMedGoogle Scholar
• Mauricio D, Zeybek B, Tymon-Rosario J, Harold J, Santin AD. Immunotherapy in cervical cancer. Curr Oncol Rep. 2021;23(6):61. doi:10.1007/s11912-021-01052-8.
   PubMed Web of Science ®Google Scholar
• Zhen S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun. 2014;450(4):1422–1426. doi:10.1016/j.bbrc.2014.07.014.
   PubMed Web of Science ®Google Scholar
• Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, et al. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int. 2014; 2014:612823. doi:10.1155/2014/612823.
   PubMed Web of Science ®Google Scholar
• Sato N, Saga Y, Uchibori R, Tsukahara T, Urabe M, Kume A, et al. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7. Int J Oncol. 2018;52(3):687–696. doi:10.3892/ijo.2018.4245.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166. doi:10.1038/nrc2602.
   PubMed Web of Science ®Google Scholar
• Lee YY, Cho YJ, Won Shin S, Choi C, Ryu JY, Jeon HK, et al. Anti-tumor effects of Wee1 kinase inhibitor with radiotherapy in human cervical cancer. Sci Rep. 2019;9(1):15394. doi:10.1038/s41598-019-51959-3.
   PubMedGoogle Scholar